ARTV

$11.52-$0.23 (-1.99%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$563.7M

49M shares

52-week range

$2.22 – $14.53

76% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-0.70

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-2.67	$-2.94–$-2.37	—	4
2027	$0	—	$-2.91	$-3.60–$-2.48	—	4
2028	$2M	—	$-3.05	$-4.48–$-2.21	—	5
2029	$41M	+2345.8%	$-2.58	$-2.58–$-2.58	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.63	$-0.63	-0.8%
2026-05-08	$-0.88	$-0.95	-8.0%
2026-03-10	$-0.87	$-0.84	+3.4%
2025-11-12	$-0.92	$-0.88	+4.3%
2025-08-06	$-0.84	$-0.87	-3.6%
2025-05-08	$-0.68	$-0.83	-22.1%
2025-03-25	$-0.71	$-0.66	+7.0%
2024-11-12	$-0.68

DCF fair valuemodel estimate

Intrinsic value

$0.66

Price

$11.52

Implied downside

-94%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ARTVArtiva Biotherapeutics, Inc.	$11.30	-1.99%	$552M	—
ADVMAdverum Biotechnologies, Inc.	$4.36	+0.00%	$96M	—
ALXOALX Oncology Holdings Inc.	$1.94	-3.48%	$261M	—
CNTBConnect Biopharma Holdings Limited	$2.54	+9.01%	$160M	—
DTILPrecision BioSciences, Inc.	$7.30

Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

www.artivabio.com

Employees: 115
IPO / List date: Jul 19, 2024
HQ: SAN DIEGO, CA

Held by traders on TradeandTell

No one on the platform currently holds ARTV.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	80,038	$515.4K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ARTV yet.

$ARTV chatter on StockTwits

Ale Lëtz@aletzBullish6d
$NKTX I like a quiet climb here. Phase 1 data imminent and phase 1s have tendency of showing primises and although the science it's not exactly the same but $ARTV has already shown strong potential and hopefully Nkarta can show it can be done without a need of mAbs. Holding both btw.
View on StockTwits ↗
doug ingber@dougdchefBullishAug 6
$ARTV The earnings report was to have come out yesterday, I believe, but I’ve seen nothing on it. Hummm
View on StockTwits ↗
Kikikikiii@KikikikiiiBullishAug 5
$ARTV 20$ end of yesr
View on StockTwits ↗
Shahid Attar@shahidattarBullishAug 5
$ARTV Can you break 12 this week?
View on StockTwits ↗
Ale Lëtz@aletzBullishAug 4
$ARTV Is RA Capital attempting to acquire all outstanding shares? 😅😅
View on StockTwits ↗
Ale Lëtz@aletzBullishAug 4
$ARTV Lack of interest on this thread is unbelievable, particularly given Artiva's exceptional performance. We are expecting significant catalysts later this year, including the initiation of Phase 3 trials and forthcoming updates on the durability of their basket study.
View on StockTwits ↗
Merlintrader Trading Pub@MerlintraderJul 30
Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
View on StockTwits ↗
Northridge G-101 SPM Company@G101SPMJul 24
#INSIDERS $ARTV 10% owner RA Capital bought 264,586 shares at $9.40 - $10 worth approximately $2.6 mln (transaction dates 7/21-7/23). ENR 10% owner bought 120,000 shares at $19.64 - $21.05 worth approximately $2.4 mln (transaction dates 7/21-7/22). $NPWR 10% owner sold 209,142 shares worth approximately $319K (transaction dates 7/21-7/23).
View on StockTwits ↗
"Teufelshunde"@SocioCobbBullishJul 24
$ARTV Interesting form 4s here. Bully!
View on StockTwits ↗
AlertsAndNews@AlertsAndNewsJul 24
$ARTV another big buy from this director. he's been buying alot since mid June. 4th buy. ARTV Artiva Biotherapeutics: Shah Rajeev M. (Director, 10%+) Buys 264,586 Shares @ Average Price of $9.76 (Form 4)
View on StockTwits ↗
Filing Tracker@FilingTrackerJul 24
$ARTV Insider purchase: https://filingtracker.ai/filing/1315082/0001231919-26-000791?doc=form4-07242026_010725.xml
View on StockTwits ↗
Capital Gains - 10X@Think_BiglyJul 22
$ARTV RA Capital trying to buy every share? Now over 17M.
View on StockTwits ↗
J@DoozioBullishJul 22
$ARTV after da final MNDY 🐑 🎁 out of the tightness da huckleberries will be below da $$$$ ENTA 🐒🍌🧠⏰♾️
View on StockTwits ↗
Yva@yvaJul 18
$ARTV Google finance says : For Artiva Biotherapeutics Inc (NASDAQ:ARTV), analysts maintain a bullish outlook for the end of 2026, with an average price target of approximately $39.00. Forecasts from major firms range from a low of $23.00 to a high of $41.00. As of July 17, 2026, the stock was trading at $9.76, meaning the consensus target represents a potential upside of nearly 300%.
View on StockTwits ↗
Capital Gains - 10X@Think_BiglyJul 17
$ARTV Buyout very probable by EOY.. maybe two buyouts. And you think.. Huh? Their RA trial is a lay up. The 3 ptr will be their 2nd target. Their advantage: Efficacy with virtually no toxicity.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.